Key PointsQuestion
Are both the peripheral and cerebral forms of microvascular dysfunction associated with late-life depression, as suggested by the vascular depression hypothesis?
Findings
This systematic review and meta-analysis of 48 studies comprising 43 600 participants, including 9203 individuals with depression, shows that the cerebral and peripheral forms of microvascular dysfunction were associated with increased odds for (incident) late-life depression, independent of cardiovascular risk factors.
Meaning
These findings support the hypothesis that microvascular dysfunction is causally linked to late-life depression. This finding may have clinical implications because microvascular dysfunction might provide a target for the prevention and treatment of depression.
Importance
The etiologic factors of late-life depression are still poorly understood. Recent evidence suggests that microvascular dysfunction is associated with depression, which may have implications for prevention and treatment. However, this association has not been systematically reviewed.
Objective
To examine the associations of peripheral and cerebral microvascular dysfunction with late-life depression.
Data Sources
A systematic literature search was conducted in MEDLINE and EMBASE for and longitudinal studies published since inception to October 16, 2016, that assessed the associations between microvascular dysfunction and depression.
Study Selection
Three independent researchers performed the study selection based on consensus. Inclusion criteria were a study population 40 years of age or older, a validated method of detecting depression, and validated measures of microvascular function.
Data Extraction and Synthesis
This systematic review and meta-analysis has been registered at PROSPERO (CRD42016049158) and is reported in accordance with the PRISMA and MOOSE guidelines. Data extraction was performed by an independent researcher.
Main Outcomes and Measures
The following 5 estimates of microvascular dysfunction were considered in participants with or without depression: plasma markers of endothelial function, albuminuria, measurements of skin and muscle microcirculation, retinal arteriolar and venular diameter, and markers for cerebral small vessel disease. Data are reported as pooled odds ratios (ORs) by use of the generic inverse variance method with the use of random-effects models.
Results
A total of 712 studies were identified; 48 were included in the meta-analysis, of which 8 described longitudinal data. Data from 43 600 participants, 9203 individuals with depression, and 72 441 person-years (mean follow-up, 3.7 years) were available. Higher levels of plasma endothelial biomarkers (soluble intercellular adhesion molecule–1: OR, 1.58; 95% CI, 1.28-1.96), white matter hyperintensities (OR, 1.29; 95% CI, 1.19-1.39), cerebral microbleeds (OR, 1.18; 95% CI, 1.03-1.34), and cerebral (micro)infarctions (OR, 1.30; 95% CI, 1.21-1.39) were associated with depression. Among the studies available, no significant associations of albuminuria and retinal vessel diameters with depression were reported. Longitudinal data showed a significant association of white matter hyperintensities with incident depression (OR, 1.19; 95% CI, 1.09-1.30).
Conclusions and Relevance
This meta-analysis shows that both the peripheral and cerebral forms of microvascular dysfunction are associated with higher odds of (incident) late-life depression. This finding may have clinical implications because microvascular dysfunction might provide a potential target for the prevention and treatment of depression.
Late-life depression is a highly prevalent and heterogeneous disease with high rates of morbidity and mortality.1,2 It is characterized by recurrent episodes: up to 50% of those who recover from a first episode of depression will experience additional episodes throughout their lifetime.3-6 Evidence suggests a cerebrovascular etiologic cause7 because late-life depression has been associated with vascular dementia, stroke, and white matter hyperintensities (WMHs).8 Moreover, a vascular etiologic cause may explain the high recurrence rate of depression, in addition to the high rate of resistance to antidepressants and/or cognitive behavioral therapy; approximately one-third of patients with depression have treatment-resistant depression.6,9,10
Several studies have provided evidence that cerebral small vessel disease may play a role in the etiologic factors of late-life depression.7,11-18 A meta-analysis from 2014, including 19 studies and 6274 participants, showed significant cross-sectional and longitudinal associations between white matter lesions, a proxy of cerebral small vessel disease, and (incident) depression.19 However, multiple studies with continuous measures of WMHs were not included in this meta-analysis, and 2 large longitudinal studies became available only recently.13,20 Furthermore, the growing evidence on alternative markers of microvascular dysfunction (for instance, on biomarkers of endothelial dysfunction) was not taken into account in previous meta-analyses.21-23
In view of these considerations, we hypothesize that microvascular dysfunction, both peripheral and cerebral, may be associated with depression. We conducted a systematic review and meta-analysis to investigate this hypothesis, both in cross-sectional and longitudinal studies.
We used MEDLINE and EMBASE to conduct a systematic literature search for cross-sectional and longitudinal epidemiologic studies of humans, determining the association between markers of microvascular dysfunction and depressive symptoms and/or depressive disorder, published from inception to October 16, 2016. This study has been registered at PROSPERO (https://www.crd.york.ac.uk/PROSPERO/ [CRD42016049158]) and is reported in accordance with the PRISMA24 and MOOSE guidelines. We considered the following 5 estimates of microvascular dysfunction: plasma markers of endothelial function, albuminuria, measurements of skin and muscle microcirculation, retinal arteriolar and venular diameter, and markers for cerebral small vessel disease. The exact search strategy and rationale are in the eAppendix in the Supplement.
Selection Criteria and Data Extraction
Three independent researchers performed the study selection (M.J.M.v.A., A.J.H.M.H., and M.T.S.). Population-based or case-control studies that reported on microvascular dysfunction in participants with or without depression were included. Figure 1 shows the selection procedure. Of the 67 studies included in the review, we extracted the following: baseline characteristics of the study population, study design, number of participants with or without depression, definition of microvascular dysfunction and depression (self-reported questionnaire vs diagnostic psychiatric interview), fully adjusted results including 95% CIs, SD, or range, and confounders included in the analyses. When these data were missing, the principal investigators were contacted for further information. If the principal investigator could not provide the missing data, the study was excluded. The quality of studies was assessed by use of the Newcastle-Ottawa Scale (NOS) for case-control and cohort studies (eTable 1 in the Supplement). This scale uses a 10-point grading system with a maximum score of 9 points for longitudinal studies, 6 points for cross-sectional cohort studies, and 8 points for case-control studies and assesses selection of study groups, comparability of groups, and ascertainment of exposure and outcome.25 We calculated the percentage of the maximum NOS score for all studies (eTable 1 in the Supplement).
We performed the meta-analysis with Review Manager, version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration), by use of the generic inverse variance method with random-effects models. In studies that reported microvascular function as mean (SD) values for participants with depression compared with controls without depression, we calculated odds ratios (ORs) based on the standardized mean difference method in concordance with the Cochrane Handbook for Systematic Reviews of Interventions.26 If only a range of scores was reported, we estimated the SD using the formula (upper limit − lower limit)/4. We used forest plots to display the pooled ORs and 95% CIs, assessed heterogeneity using I2 statistics (values of 50%-75% indicated moderate heterogeneity, and values of >75% indicated considerable heterogeneity),26-28 and determined the risk of publication bias by visual inspection of funnel plots, the Egger test, and the trim-and-fill method.26,29,30 We performed subgroup and meta-regression analysis with R31 to explore heterogeneity, and we evaluated the methods to assess depression (diagnostic interviews vs self-reported questionnaires), study design (case-control vs cohort study), methods to assess WMHs (semiautomatic volumetry vs subjective rating scale), and study quality as assessed by the NOS score (≥60% vs <60%).
Study Selection and Characteristics
We identified 712 studies, of which 90 full-text articles were assessed for eligibility. Of these, we selected 67 studies that investigated whether microvascular dysfunction was associated with depressive disorder or depressive symptoms. Of these studies, 59 had a cross-sectional design (35 case-control studies and 24 cohort studies), and 8 had a longitudinal design (8 cohort studies). In total, data from 43 600 participants, including 9203 individuals (21.1%) with depression, were included in the meta-analysis. The mean age of participants was 66 years, and 23 544 were female (54.0%). In total, 72 441 person-years were included in longitudinal analyses (mean [SD] follow-up, 3.7 [0.7] years). We found no studies that investigated the association between skin and muscle microcirculation and depressive disorder or depressive symptoms.
All studies included in the review used a dichotomous outcome measure for depression, either by use of a diagnostic interview to assess major depressive disorder or by use of a cutoff for clinically relevant depressive symptoms, including the Mini International Neuropsychiatric Interview or the Structured Clinical Interview for DSM for depressive disorder and the Centers for Epidemiological Studies Depression Scale, the Geriatric Depression Scale, the Hamilton Depression Rating Scale, the Beck Depression Inventory, and the Montgomery-Asberg Depression Rating Scale for clinically relevant depressive symptoms. Plasma samples of biomarkers (soluble intercellular adhesion molecule-1 [sICAM-1], soluble vascular cell adhesion molecule-1 [sVCAM-1], e-selectin, and von Willebrand factor [vWF]) for endothelial function were all analyzed by the use of an enzyme-linked immunosorbent assay. Albuminuria was measured by use of the albumin to creatinine ratio or 24-hour urinary albumin excretion. Retinal vessel calibers were measured by the use of stereoscopic color fundus photography. Cerebral small vessel disease was determined by magnetic resonance imaging–defined automated segmentation of WMH volume (33 studies), rating scales for WMH severity (22 studies), microbleeds (4 studies), and/or lacunar or silent infarctions (4 studies). Characteristics of all selected studies are presented in eTable 2 in the Supplement and the outcomes of the selected studies in eTable 3 in the Supplement.
Association of Endothelial Function With Depression
Eight studies investigated the cross-sectional associations between plasma markers of endothelial function and depressive symptoms (n = 6) or depressive disorder (n = 4).21,32-38 Most studies observed that higher levels of endothelial plasma markers, which indicate dysfunction, were associated with depression.32,33,35-38 One study described lower sVCAM-1 levels,34 and another study lower e-selectin levels,21 in participants with depression compared with controls without depression.
Seven studies21,32-35,37,38 were included in the meta-analysis on plasma markers of endothelial function (1 study provided insufficient data36). We found a significant association between higher levels of plasma markers of endothelial function and depression (Figure 2; pooled OR per SD increase of sICAM-1, 1.58; 95% CI, 1.28-1.96; P < .001; I2 = 35%; pooled OR per SD increase of sVCAM-1, 1.82; 95% CI, 1.03-3.22; P < .001; I2 = 81%; pooled OR per SD increase of e-selectin, 1.04; 95% CI, 0.64-1.70; P = .87; I2 = 66%; pooled OR per SD increase of vWF, 1.80; 95% CI, 0.67-4.86; P = .25; I2 = 77%). We found no evidence of publication bias by the inspection of the funnel plots (eFigure 1 in the Supplement) or the Egger test (t = 1.569; P = .12).
Association of Albuminuria With Depression
Two studies investigated the association between albuminuria and depression.22,23 Albuminuria was not significantly associated with depression in patients with (OR, 1.29; 95% CI, 0.96-1.73) or without (OR, 1.07; 95% CI, 0.70-1.63) prior cardiovascular disease.22 A second study23 found no significant association between urinary protein (milligrams per gram) and depressive symptoms in participants with chronic kidney disease (OR, 1.07; 95% CI, 0.90-1.26).
Association of Retinal Microvascular Diameters With Depression
Two studies investigated the association between retinal arteriolar and venular diameters and depression.39,40 In a subpopulation of participants with diabetes, significant differences were found between controls (mean [SD] arteriolar diameter, 133.1 [5.5] µm; mean [SD] venular diameter, 214.2 [7.5] µm), patients with diabetes (mean [SD] arteriolar diameter, 135.7 [5.6] µm; mean [SD] venular diameter, 208.7 [7.6] µm), and patients with depression and diabetes (mean [SD] arteriolar diameter, 140.3 [5.8]; P < .01 for trend; mean [SD] venular diameter 209.9 [7.9]; P = .03 for trend).39 In contrast, a large longitudinal cohort study found no association between retinal arteriolar and venular diameters and incident major depressive disorder during 9 years of follow-up (hazard ratio per SD increase in arteriolar diameter, 1.01; 95% CI, 0.93-1.10; and hazard ratio per SD increase in venular diameter, 1.02; 95% CI, 0.94-1.12).40
Cross-sectional Association of Cerebral Small Vessel Disease With Depression
Fifty-five studies investigated the association between cerebral small vessel disease and depression,11,13,14,17,20,41-91 of which 8 studies had a prospective design.13,20,70,84,85,88-90 Most studies focused on WMH volumes or WMH severity scores in a case-control or a population-based cohort setting. In addition to studying WMHs, 4 studies also evaluated the association of microbleeds and microinfarctions with depression.13,51,82,91 Overall, cerebral small vessel disease was associated with depression.
Thirty-eight studies11,13,17,44-47,49,51-58,60-64,66,73,75-88,91 were included in the meta-analysis on cross-sectional data (Figure 3; eFigure 2 and eFigure 3 in the Supplement). A significant association between WMHs and depression was found (pooled OR per SD, 1.29; 95% CI, 1.19-1.39; P < .001; I2 = 66%). A statistically significant association was found between a higher number of microbleeds (pooled OR, 1.18; 95% CI, 1.03-1.34; P < .05; I2 = 0%) and brain (micro)infarctions (pooled OR, 1.30; 95% CI, 1.21-1.39; P < .001; I2 = 1%) and depression. To reduce possible residual confounding by medical comorbidities, we restricted the analysis to studies that corrected for diabetes status or hypertension. The results remained statistically significant when pooling the WMH studies that corrected for diabetes status (8 studies13,51,57,60,75,76,84,91; OR, 1.32; 95% CI, 1.15-1.52; P < .001; I2 = 46%) or hypertension (11 studies13,54,55,57,63,73,75,76,83,84,91; OR, 1.18; 95% CI, 1.08-1.29; P < .001; I2 = 76%). When we restricted the analyses to the 16 studies that used a diagnostic interview to diagnose depressive disorder, the pooled OR was 1.34 per SD (95% CI, 1.19-1.51; P < .001; I2 = 24%).17,44,46,47,55,58,61,64,77,79-84,91 Twenty-two studies used questionnaires to assess depressive symptoms; pooling of these studies resulted in an OR of 1.24 per SD (95% CI, 1.14-1.35; P < .001; I2 = 69%).11,13,45,49,51-54,56,57,60,62,63,66,73,75,76,78,85-88 We further explored heterogeneity by comparing WMHs as assessed semiautomatically13,17,45-47,52,53,55,56,58,64,75,76,78-80,83-88,91 vs severity rating scales11,44,49,51,54,57,60-63,66,73,77,81,82 (OR, 1.31; 95% CI, 1.18-1.46; P < .001; I2 = 49% vs OR, 1.22; 1.10-1.34; P < .001; I2 = 66%) and case-control17,44-46,49,53,54,56-58,61,62,64,66,75,77,79-88 vs cohort studies11,13,47,51,52,55,60,63,73,76,78,91 (OR, 1.36; 95% CI, 1.22-1.52; P < .001; I2 = 37% vs OR, 1.19; 95% CI, 1.08-1.31; P < .001; I2 = 74%). We restricted analysis to 31 studies11,13,44-47,49,51,53-58,60-64,75-77,80-87,91 with a high methodological quality, as indicated by a NOS score of 60% or more.25 White matter hyperintensities were positively associated with depression (pooled OR, 1.35; 95% CI, 1.22-1.50; P < .001; I2 = 68%). Of these studies, 12 used a diagnostic interview.44,46,47,53,55,61,64,77,80-82,84 Restricting the analyses to these 12 studies resulted in a pooled OR of 1.33 (95% CI, 1.13-1.57; P < .001; I2 = 43%). The pooled OR for the 19 studies that used questionnaires was 1.32 (95% CI, 1.17-1.49; P < .001; I2 = 70%).11,13,45,49,51,53,54,56,57,60,62,63,75,76,83,85-87,91 In meta-regression analysis, we found a significant association between WMHs and depression (pooled OR per SD, 1.25; 95% CI, 1.05-1.49; P < .05; I2 = 51%) when we included the methods to assess depression (diagnostic interviews vs self-reported questionnaires), study design (case-control vs cohort study), and methods to assess WMHs (semiautomatic volumetry vs subjective rating scale). We found no evidence of publication bias by the inspection of the funnel plots (eFigure 1 in the Supplement), the Egger test (t = 1.569; P = .29), or the trim-and-fill (eFigure 4 in the Supplement). Owing to the limited number of studies, we could not perform subgroup analyses or valid estimations on publication bias for data on microbleeds and microinfarctions.
Longitudinal Association of Cerebral Small Vessel Disease With Depression
Eight studies were included in the meta-analysis of longitudinal data (Figure 4).13,20,70,84,85,88-90 Only data on WMHs could be pooled, because only 1 longitudinal study13 investigated the association of microbleeds and brain infarctions with depression. As shown in Figure 4, a statistically significant association between WMHs and the incidence of depression was found (pooled OR, 1.18; 95% CI, 1.08-1.28; P < .001; I2 = 27%) over a mean follow-up of 3.7 years. We found no evidence of publication bias based on the funnel plots (eFigure 5 in the Supplement) or the Egger test (t = 1.139; P = .30).
This extensive meta-analysis on 43 600 participants, including 9203 individuals with depression, shows that generalized microvascular dysfunction is associated with depression, both in cross-sectional and longitudinal settings, independent of cardiovascular risk factors. Multiple markers of microvascular dysfunction, including endothelial plasma markers and markers of cerebral small vessel disease, are cross-sectionally associated with a higher level of depressive symptoms and depressive disorder. In addition, WMHs are associated with incident depression over time. These findings are in agreement with the vascular depression hypothesis and extend this hypothesis, as peripheral microvascular dysfunction may also be associated with depression.92,93
In this systematic review with meta-analysis, we evaluated the associations between microvascular dysfunction and depression. We included cross-sectional and longitudinal epidemiologic studies, and are the first, to our knowledge, to consider the association of multiple measures of both cerebral and peripheral microvascular dysfunction with depression. By combining the extensive evidence on WMHs with data from biomarkers of endothelial function, we aim to provide further evidence for the hypothesis that cerebral small vessel disease may originate from endothelial dysfunction. We suggest that generalized microvascular dysfunction, as can be measured throughout the body, is an important pathophysiologic factor that may contribute to the development of depression. Our results confirm and extend 2 previous meta-analyses that addressed the association between WMHs and depression19,94 by including more than 6 times the number of participants and depression cases, thus increasing statistical power. This number enabled us to overcome the major caveat of high heterogeneity, which was a major methodological issue in previous meta-analyses. The use of diagnostic interviews vs questionnaires to assess depression, and case-control vs cohort study design were found to be the sources of heterogeneity, which has important implications for future studies that investigate the pathophysiologic factors of depression. These variables, however, did not affect the observed associations, which strengthens the validity of our findings. Finally, our study focused on late-life depression, in which vascular pathologic conditions are thought to have the greatest effect, while previous meta-analyses combined early and late-life depression.19,94
The association of microvascular dysfunction with depression can be explained by several mechanisms. First, impaired endothelial function in the cerebral microcirculation may lead to cerebral perfusion deficits, resulting in chronic ischemia in the cerebrum.95 Chronic ischemia could cause structural disruptions of the fiber tracts in the cerebral white matter, which are visualized as WMHs on results of magnetic resonance imaging.95-98 If the affected regions are involved in mood regulation, this may predispose the individual to the development of depression. Second, microvascular dysfunction is closely linked to and interrelated with chronic low-grade inflammation and/or oxidative stress, which may represent different pathways in the development of depression.35,99-102 Low-grade inflammation is known to contribute to endothelial dysfunction.21,35 In addition, the cerebral endothelium may be more vulnerable to oxidative stress, owing to a high production of reactive oxygen species in the brain as a result of the high metabolic demand.103 Moreover, the brain has limited antioxidant defenses,104 while damage related to oxidative stress has been described in psychiatric disease105-107 and may contribute to cerebral dysfunction. However, multiple studies have shown that the association between microvascular dysfunction and depression is only partly dependent on inflammation21,35,36 or oxidative stress,21 which suggests that microvascular dysfunction itself represents an independent pathway in the development of depression. Third, cardiometabolic risk factors may be involved in the association between microvascular dysfunction and depression. For instance, increased arterial stiffening may induce microvascular disease and is related to depression.108 Increased arterial stiffness leads to an increased pulsatile pressure load, which, owing to the low impedance of the cerebral microcirculation, can penetrate deeply into the white matter, thereby inducing microvascular dysfunction and WMHs.108-110 In addition, other cardiometabolic risk factors, such as decreased physical activity,111 smoking,112 obesity,113 hypertension,113-115 diabetes,114,115 and unhealthy diet,98,116,117 have been associated with both microvascular dysfunction and depression. However, we mainly used results that were adjusted for cardiometabolic risk factors in our meta-analysis. This finding may suggest that microvascular dysfunction represents an independent pathway in the development of depression. Fourth, acute and chronic stress can result in autonomic and hypothalamic-pituitary-adrenal axis dysregulation, which in turn can contribute to both depression and cardiovascular disease.118 Stress-induced elevated cortisol levels may cause cerebral atrophy, reduced neurogenesis, synaptic plasticity, and monoaminergic signaling, all of which could contribute to the development of depression.119
The exact pathogenesis of WMHs is currently undetermined. Several studies have assumed that WMHs are due to ischemia7,8,120,121; however, evidence indicates that WMHs originate from cerebral endothelial dysfunction.122 This evidence is supported by findings that WMHs and microinfarctions are associated with leakage of plasma fluid components, arteriolar wall infiltration, thickening of the arteriolar wall, and changes in perivascular tissue, causing disruption of the normal architecture, including damaged arteriolar smooth muscle cells and fibrin depositions. In addition, the specific anatomy of capillaries (with functional shunts and tight control of capillary flow patterns) could enable 2 distinct mechanisms to induce ischemia within the brain: limited blood supply and limited oxygen extraction due to capillary dysfunction.123
Strengths and Limitations
The strengths of this study include the large number of included studies and individuals with depression, resulting in high statistical power, which allowed an extensive exploration of the cause of heterogeneity within the meta-analysis. This meta-analysis is limited by the available literature. Based on the available data, we cannot rule out the possibility of reverse causality. It is plausible to assume that the association between microvascular dysfunction and depression is bidirectional; that is, microvascular dysfunction may cause depression, and vice versa. The proposed temporality was supported by the longitudinal association for WMHs and depression, but could not be confirmed for other markers of microvascular dysfunction. Further longitudinal studies are needed to address this issue. In addition, the interrelationships among medical comorbidities, microvascular dysfunction, and depression could only partly be assessed. Therefore, an important limitation of this meta-analysis and indeed of the source studies is that we cannot exclude residual confounding by variables not considered in the source studies. However, based on our subanalyses, confounding by type 2 diabetes, hypertension, and cardiovascular risk factors is unlikely. In addition, some of the indicators of vascular dysfunction, such as albuminuria, may be less specific and may more likely reflect a general health status, which could have led to an overestimation of the association. Furthermore, most studies on plasma biomarkers of endothelial dysfunction measured multiple biomarkers; therefore, we did not calculate a pooled estimate. Nevertheless, when focusing on the pooled ORs per specific biomarker, the 95% CIs were virtually within the same range. Finally, data on the association between albuminuria, retinal diameters, and depression appeared to be scarce, while data on albuminuria were available only in study populations with disease, and therefore cannot be extrapolated to the general population.
As the cerebral microvasculature is difficult to study, there is a need to develop more advanced and powerful imaging techniques, such as 7-T magnetic resonance imaging and diffuse tensor imaging, which may provide more sensitive research tools with more detailed structural information on microvascular changes as seen in cerebral small vessel disease.124-127 Furthermore, several state-of-the-art techniques have been developed to investigate the microcirculation throughout the body, such as sublingual intravital microscopy,128 skin laser-Doppler flowmetry,113,129 dynamic retinal vessel analysis,129 and skin capillaroscopy.130 Large-scale studies using these new techniques are of crucial importance to unravel the association between microvascular dysfunction and depression. In addition, experimental studies are needed to demonstrate the possible causal role of microvascular dysfunction in depression. Multiple drugs, such as angiotensin-converting enzyme inhibitors131 and statins,132,133 as well as lifestyle interventions134,135 have been shown to improve microvascular function; it is not known, however, whether such interventions can improve brain microcirculatory function in general or WMHs specifically.136 Some evidence exists that angiotensin-converting enzyme inhibitors may be efficacious in the treatment of depression.137-139 However, larger randomized trials have not been performed. Statins may provide another intervention of interest in depression, although the current literature reports conflicting results.140-145 Randomized clinical trials in individuals at high risk for or with depression may provide further insight into the role of microcirculatory dysfunction in the prevention and/or treatment of depression.
This meta-analysis shows that generalized microvascular dysfunction is associated with higher odds of depression and that cerebral small vessel disease is associated with an increased risk for the development of depression over time. These findings support the hypothesis that microvascular dysfunction is causally linked to depression. This finding may have clinical implications, as microvascular dysfunction might provide a potential target for the prevention and treatment of depression.
Accepted for Publication: March 26, 2017.
Corresponding Author: Miranda T. Schram, MD, Department of Internal Medicine, Maastricht University Medical Centre, Randwycksingel 35, Maastricht, Limburg 6229 EG, the Netherlands (m.schram@maastrichtuniversity.nl).
Published Online: May 31, 2017. doi:10.1001/jamapsychiatry.2017.0984
Author Contributions: Dr Schram had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: van Agtmaal, Houben, Stehouwer, Schram.
Acquisition, analysis, or interpretation of data: van Agtmaal, Houben, Pouwer, Schram.
Drafting of the manuscript: van Agtmaal, Houben, Pouwer, Schram.
Critical revision of the manuscript for important intellectual content: Houben, Pouwer, Stehouwer, Schram.
Statistical analysis: van Agtmaal, Schram.
Obtained funding: Houben, Stehouwer.
Administrative, technical, or material support: van Agtmaal, Stehouwer, Schram.
Study supervision: Houben, Pouwer, Stehouwer, Schram.
Conflict of Interest Disclosures: None reported.
Funding/Support: This research was supported by the Stichting Annadal and Health Foundation Limburg.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
2.Whiteford
HA, Degenhardt
L, Rehm
J,
et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.
Lancet. 2013;382(9904):1575-1586.
PubMedGoogle ScholarCrossref 3.Driscoll
HC, Basinski
J, Mulsant
BH,
et al. Late-onset major depression: clinical and treatment-response variability.
Int J Geriatr Psychiatry. 2005;20(7):661-667.
PubMedGoogle ScholarCrossref 4.Hardeveld
F, Spijker
J, De Graaf
R,
et al. Recurrence of major depressive disorder across different treatment settings: results from the NESDA study.
J Affect Disord. 2013;147(1-3):225-231.
PubMedGoogle ScholarCrossref 5.Hardeveld
F, Spijker
J, De Graaf
R, Nolen
WA, Beekman
AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population.
Acta Psychiatr Scand. 2010;122(3):184-191.
PubMedGoogle ScholarCrossref 6.Trivedi
MH, Rush
AJ, Wisniewski
SR,
et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Am J Psychiatry. 2006;163(1):28-40.
PubMedGoogle ScholarCrossref 7.Alexopoulos
GS, Meyers
BS, Young
RC, Campbell
S, Silbersweig
D, Charlson
M. ‘Vascular depression’ hypothesis.
Arch Gen Psychiatry. 1997;54(10):915-922.
PubMedGoogle ScholarCrossref 9.Paroni
G, Seripa
D, Fontana
A,
et al.
Klotho gene and selective serotonin reuptake inhibitors: response to treatment in late-life major depressive disorder.
Mol Neurobiol. 2017;54(2):1340-1351.
PubMedGoogle ScholarCrossref 11.de Groot
JC, de Leeuw
FE, Oudkerk
M, Hofman
A, Jolles
J, Breteler
MM. Cerebral white matter lesions and depressive symptoms in elderly adults.
Arch Gen Psychiatry. 2000;57(11):1071-1076.
PubMedGoogle ScholarCrossref 13.van Sloten
TT, Sigurdsson
S, van Buchem
MA,
et al. Cerebral small vessel disease and association with higher incidence of depressive symptoms in a general elderly population: the AGES-Reykjavik Study.
Am J Psychiatry. 2015;172(6):570-578.
PubMedGoogle ScholarCrossref 14.Direk
N, Koudstaal
PJ, Hofman
A, Ikram
MA, Hoogendijk
WJ, Tiemeier
H. Cerebral hemodynamics and incident depression: the Rotterdam Study.
Biol Psychiatry. 2012;72(4):318-323.
PubMedGoogle ScholarCrossref 15.Bakker
SL, de Leeuw
FE, de Groot
JC, Hofman
A, Koudstaal
PJ, Breteler
MM. Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly.
Neurology. 1999;52(3):578-583.
PubMedGoogle ScholarCrossref 16.Van den Berg
MD, Oldehinkel
AJ, Bouhuys
AL, Brilman
EI, Beekman
AT, Ormel
J. Depression in later life: three etiologically different subgroups.
J Affect Disord. 2001;65(1):19-26.
PubMedGoogle ScholarCrossref 17.Paranthaman
R, Greenstein
AS, Burns
AS,
et al. Vascular function in older adults with depressive disorder.
Biol Psychiatry. 2010;68(2):133-139.
PubMedGoogle ScholarCrossref 18.Taylor
WD, Kudra
K, Zhao
Z, Steffens
DC, MacFall
JR. Cingulum bundle white matter lesions influence antidepressant response in late-life depression: a pilot study.
J Affect Disord. 2014;162:8-11.
PubMedGoogle ScholarCrossref 19.Wang
L, Leonards
CO, Sterzer
P, Ebinger
M. White matter lesions and depression: a systematic review and meta-analysis.
J Psychiatr Res. 2014;56:56-64.
PubMedGoogle ScholarCrossref 20.Saavedra Perez
HC, Direk
N, Hofman
A, Vernooij
MW, Tiemeier
H, Ikram
MA. Silent brain infarcts: a cause of depression in the elderly?
Psychiatry Res. 2013;211(2):180-182.
PubMedGoogle ScholarCrossref 21.van Sloten
TT, Schram
MT, Adriaanse
MC,
et al. Endothelial dysfunction is associated with a greater depressive symptom score in a general elderly population: the Hoorn Study.
Psychol Med. 2014;44(7):1403-1416.
PubMedGoogle ScholarCrossref 22.Katon
WJ, Lin
EH, Russo
J,
et al. Cardiac risk factors in patients with diabetes mellitus and major depression.
J Gen Intern Med. 2004;19(12):1192-1199.
PubMedGoogle ScholarCrossref 23.Fischer
MJ, Xie
D, Jordan
N,
et al; CRIC Study Group Investigators. Factors associated with depressive symptoms and use of antidepressant medications among participants in the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic-CRIC Studies.
Am J Kidney Dis. 2012;60(1):27-38.
PubMedGoogle ScholarCrossref 24.Moher
D, Liberati
A, Tetzlaff
J, Altman
DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
BMJ. 2009;339:b2535.
PubMedGoogle ScholarCrossref 26.Higgins
JPT, Green
S, eds. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. Chichester, England: The Cochrane Collaboration/Wiley; 2011.
27.Dinnes
J, Deeks
J, Kirby
J, Roderick
P. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy.
Health Technol Assess. 2005;9(12):1-113, iii.
PubMedGoogle ScholarCrossref 29.Egger
M, Davey Smith
G, Schneider
M, Minder
C. Bias in meta-analysis detected by a simple, graphical test.
BMJ. 1997;315(7109):629-634.
PubMedGoogle ScholarCrossref 30.Duval
S, Tweedie
R. Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis.
Biometrics. 2000;56(2):455-463.
PubMedGoogle ScholarCrossref 31.R Development Core Team. R: A Language and Environment for Statistical Computing. Version 3.3.1. Vienna, Austria: R Foundation for Statistical Computing; 2011.
32.Dimopoulos
N, Piperi
C, Salonicioti
A,
et al. Elevation of plasma concentration of adhesion molecules in late-life depression.
Int J Geriatr Psychiatry. 2006;21(10):965-971.
PubMedGoogle ScholarCrossref 33.Lespérance
F, Frasure-Smith
N, Théroux
P, Irwin
M. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes.
Am J Psychiatry. 2004;161(2):271-277.
PubMedGoogle ScholarCrossref 34.Thomas
AJ, Morris
C, Davis
S, Jackson
E, Harrison
R, O’Brien
JT. Soluble cell adhesion molecules in late-life depression.
Int Psychogeriatr. 2007;19(5):914-920.
PubMedGoogle ScholarCrossref 35.van Dooren
FE, Schram
MT, Schalkwijk
CG,
et al. Associations of low grade inflammation and endothelial dysfunction with depression—the Maastricht Study.
Brain Behav Immun. 2016;56:390-396.
PubMedGoogle ScholarCrossref 36.Do
DP, Dowd
JB, Ranjit
N, House
JS, Kaplan
GA. Hopelessness, depression, and early markers of endothelial dysfunction in US adults.
Psychosom Med. 2010;72(7):613-619.
PubMedGoogle ScholarCrossref 37.Tchalla
AE, Wellenius
GA, Sorond
FA, Travison
TG, Dantoine
T, Lipsitz
LA. Elevated circulating vascular cell adhesion molecule-1 (sVCAM-1) is associated with concurrent depressive symptoms and cerebral white matter hyperintensities in older adults.
BMC Geriatr. 2015;15:62.
PubMedGoogle ScholarCrossref 38.Tully
PJ, Baumeister
H, Martin
S,
et al; Florey Adelaide Male Ageing Study. Elucidating the biological mechanisms linking depressive symptoms with type 2 diabetes in men: the longitudinal effects of inflammation, microvascular dysfunction, and testosterone.
Psychosom Med. 2016;78(2):221-232.
PubMedGoogle ScholarCrossref 39.Nguyen
TT, Wong
TY, Islam
FM,
et al. Evidence of early retinal microvascular changes in patients with type 2 diabetes and depression.
Psychosom Med. 2010;72(6):535-538.
PubMedGoogle ScholarCrossref 40.Ikram
MK, Luijendijk
HJ, Hofman
A,
et al. Retinal vascular calibers and risk of late-life depression: The Rotterdam Study.
Am J Geriatr Psychiatry. 2010;18(5):452-455.
PubMedGoogle ScholarCrossref 41.Aizenstein
HJ, Andreescu
C, Edelman
KL,
et al. fMRI correlates of white matter hyperintensities in late-life depression.
Am J Psychiatry. 2011;168(10):1075-1082.
PubMedGoogle ScholarCrossref 43.Bella
R, Pennisi
G, Cantone
M,
et al. Clinical presentation and outcome of geriatric depression in subcortical ischemic vascular disease.
Gerontology. 2010;56(3):298-302.
PubMedGoogle ScholarCrossref 44.Chatterjee
K, Fall
S, Barer
D. Mood after stroke: a case control study of biochemical, neuro-imaging and socio-economic risk factors for major depression in stroke survivors.
BMC Neurol. 2010;10:125.
PubMedGoogle ScholarCrossref 45.Chen
Y, Chen
X, Mok
VC, Lam
WW, Wong
KS, Tang
WK. Poststroke depression in patients with small subcortical infarcts.
Clin Neurol Neurosurg. 2009;111(3):256-260.
PubMedGoogle ScholarCrossref 46.Colloby
SJ, Vasudev
A, O’Brien
JT, Firbank
MJ, Parry
SW, Thomas
AJ. Relationship of orthostatic blood pressure to white matter hyperintensities and subcortical volumes in late-life depression.
Br J Psychiatry. 2011;199(5):404-410.
PubMedGoogle ScholarCrossref 47.Cyprien
F, Courtet
P, Poulain
V,
et al. Corpus callosum size may predict late-life depression in women: a 10-year follow-up study.
J Affect Disord. 2014;165:16-23.
PubMedGoogle ScholarCrossref 48.Dalby
RB, Chakravarty
MM, Ahdidan
J,
et al. Localization of white-matter lesions and effect of vascular risk factors in late-onset major depression.
Psychol Med. 2010;40(8):1389-1399.
PubMedGoogle ScholarCrossref 49.Delaloye
C, Moy
G, de Bilbao
F,
et al. Neuroanatomical and neuropsychological features of elderly euthymic depressed patients with early- and late-onset.
J Neurol Sci. 2010;299(1-2):19-23.
PubMedGoogle ScholarCrossref 50.Dotson
VM, Zonderman
AB, Kraut
MA, Resnick
SM. Temporal relationships between depressive symptoms and white matter hyperintensities in older men and women.
Int J Geriatr Psychiatry. 2013;28(1):66-74.
PubMedGoogle ScholarCrossref 51.Feng
C, Fang
M, Xu
Y, Hua
T, Liu
XY. Microbleeds in late-life depression: comparison of early- and late-onset depression.
Biomed Res Int. 2014;2014:682092.
PubMedGoogle Scholar 52.Firbank
MJ, O’Brien
JT, Pakrasi
S,
et al. White matter hyperintensities and depression—preliminary results from the LADIS study.
Int J Geriatr Psychiatry. 2005;20(7):674-679.
PubMedGoogle ScholarCrossref 53.Fujishima
M, Maikusa
N, Nakamura
K, Nakatsuka
M, Matsuda
H, Meguro
K. Mild cognitive impairment, poor episodic memory, and late-life depression are associated with cerebral cortical thinning and increased white matter hyperintensities.
Front Aging Neurosci. 2014;6:306.
PubMedGoogle ScholarCrossref 54.Greenwald
BS, Kramer-Ginsberg
E, Krishnan
KR, Ashtari
M, Auerbach
C, Patel
M. Neuroanatomic localization of magnetic resonance imaging signal hyperintensities in geriatric depression.
Stroke. 1998;29(3):613-617.
PubMedGoogle ScholarCrossref 55.Gudmundsson
LS, Scher
AI, Sigurdsson
S,
et al. Migraine, depression, and brain volume: the AGES-Reykjavik Study.
Neurology. 2013;80(23):2138-2144.
PubMedGoogle ScholarCrossref 56.Hannestad
J, Taylor
WD, McQuoid
DR,
et al. White matter lesion volumes and caudate volumes in late-life depression.
Int J Geriatr Psychiatry. 2006;21(12):1193-1198.
PubMedGoogle ScholarCrossref 57.Iosifescu
DV, Papakostas
GI, Lyoo
IK,
et al. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder: part I.
Psychiatry Res. 2005;140(3):291-299.
PubMedGoogle ScholarCrossref 58.Janssen
J, Hulshoff Pol
HE, Lampe
IK,
et al. Hippocampal changes and white matter lesions in early-onset depression.
Biol Psychiatry. 2004;56(11):825-831.
PubMedGoogle ScholarCrossref 59.Janssen
J, Hulshoff Pol
HE, Schnack
HG,
et al. Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression.
Int J Geriatr Psychiatry. 2007;22(5):468-474.
PubMedGoogle ScholarCrossref 60.Jorm
AF, Anstey
KJ, Christensen
H,
et al. MRI hyperintensities and depressive symptoms in a community sample of individuals 60-64 years old.
Am J Psychiatry. 2005;162(4):699-705.
PubMedGoogle ScholarCrossref 62.Köhler
S, Thomas
AJ, Lloyd
A, Barber
R, Almeida
OP, O’Brien
JT. White matter hyperintensities, cortisol levels, brain atrophy and continuing cognitive deficits in late-life depression.
Br J Psychiatry. 2010;196(2):143-149.
PubMedGoogle ScholarCrossref 63.Krishnan
MS, O’Brien
JT, Firbank
MJ,
et al. LADIS Group. Relationship between periventricular and deep white matter lesions and depressive symptoms in older people: The LADIS Study.
Int J Geriatr Psychiatry. 2006;21(10):983-989.
PubMedGoogle ScholarCrossref 65.Lee
SH, Payne
ME, Steffens
DC,
et al. Subcortical lesion severity and orbitofrontal cortex volume in geriatric depression.
Biol Psychiatry. 2003;54(5):529-533.
PubMedGoogle ScholarCrossref 66.Lin
HF, Kuo
YT, Chiang
IC, Chen
HM, Chen
CS. Structural abnormality on brain magnetic resonance imaging in late-onset major depressive disorder.
Kaohsiung J Med Sci. 2005;21(9):405-411.
PubMedGoogle ScholarCrossref 68.Murray
AD, Staff
RT, McNeil
CJ,
et al. Depressive symptoms in late life and cerebrovascular disease: the importance of intelligence and lesion location.
Depress Anxiety. 2013;30(1):77-84.
PubMedGoogle ScholarCrossref 69.Nys
GM, van Zandvoort
MJ, van der Worp
HB, de Haan
EH, de Kort
PL, Kappelle
LJ. Early depressive symptoms after stroke: neuropsychological correlates and lesion characteristics.
J Neurol Sci. 2005;228(1):27-33.
PubMedGoogle ScholarCrossref 71.Shimony
JS, Sheline
YI, D’Angelo
G,
et al. Diffuse microstructural abnormalities of normal-appearing white matter in late life depression: a diffusion tensor imaging study.
Biol Psychiatry. 2009;66(3):245-252.
PubMedGoogle ScholarCrossref 72.Sheline
YI, Price
JL, Vaishnavi
SN,
et al. Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors.
Am J Psychiatry. 2008;165(4):524-532.
PubMedGoogle ScholarCrossref 73.Steffens
DC, Helms
MJ, Krishnan
KR, Burke
GL. Cerebrovascular disease and depression symptoms in the cardiovascular health study.
Stroke. 1999;30(10):2159-2166.
PubMedGoogle ScholarCrossref 74.Tang
WK, Chen
YK, Lu
JY,
et al. White matter hyperintensities in post-stroke depression: a case control study.
J Neurol Neurosurg Psychiatry. 2010;81(12):1312-1315.
PubMedGoogle ScholarCrossref 75.Taylor
WD, MacFall
JR, Payne
ME,
et al. Greater MRI lesion volumes in elderly depressed subjects than in control subjects.
Psychiatry Res. 2005;139(1):1-7.
PubMedGoogle ScholarCrossref 76.Tudorascu
DL, Rosano
C, Venkatraman
VK,
et al. Multimodal MRI markers support a model of small vessel ischemia for depressive symptoms in very old adults.
Psychiatry Res. 2014;224(2):73-80.
PubMedGoogle ScholarCrossref 77.Tupler
LA, Krishnan
KR, McDonald
WM, Dombeck
CB, D’Souza
S, Steffens
DC. Anatomic location and laterality of MRI signal hyperintensities in late-life depression.
J Psychosom Res. 2002;53(2):665-676.
PubMedGoogle ScholarCrossref 78.van Uden
IWM, van Norden
AGW, de Laat
KF,
et al. Depressive symptoms and amygdala volume in elderly with cerebral small vessel disease: The RUN DMC Study.
J Aging Res. 2011;2011:647869. doi:
10.4061/2011/647869Google ScholarCrossref 79.Vardi
N, Freedman
N, Lester
H,
et al. Hyperintensities on T2-weighted images in the basal ganglia of patients with major depression: cerebral perfusion and clinical implications.
Psychiatry Res. 2011;192(2):125-130.
PubMedGoogle ScholarCrossref 80.Vataja
R, Pohjasvaara
T, Leppävuori
A,
et al. Magnetic resonance imaging correlates of depression after ischemic stroke.
Arch Gen Psychiatry. 2001;58(10):925-931.
PubMedGoogle ScholarCrossref 81.Videbech
P, Ravnkilde
B, Fiirgaard
B,
et al. Structural brain abnormalities in unselected in-patients with major depression.
Acta Psychiatr Scand. 2001;103(4):282-286.
PubMedGoogle ScholarCrossref 82.Wu
RH, Feng
C, Xu
Y, Hua
T, Liu
XY, Fang
M. Late-onset depression in the absence of stroke: associated with silent brain infarctions, microbleeds and lesion locations.
Int J Med Sci. 2014;11(6):587-592.
PubMedGoogle ScholarCrossref 83.Devantier
TA, Nørgaard
BL, Poulsen
MK,
et al. White matter lesions, carotid and coronary atherosclerosis in late-onset depression and healthy controls.
Psychosomatics. 2016;57(4):369-377.
PubMedGoogle ScholarCrossref 84.Godin
O, Dufouil
C, Maillard
P,
et al. White matter lesions as a predictor of depression in the elderly: the 3C-Dijon study.
Biol Psychiatry. 2008;63(7):663-669.
PubMedGoogle ScholarCrossref 85.Grool
AM, Gerritsen
L, Zuithoff
NP, Mali
WP, van der Graaf
Y, Geerlings
MI. Lacunar infarcts in deep white matter are associated with higher and more fluctuating depressive symptoms during three years follow-up.
Biol Psychiatry. 2013;73(2):169-176.
PubMedGoogle ScholarCrossref 86.Lavretsky
H, Zheng
L, Weiner
MW,
et al. The MRI brain correlates of depressed mood, anhedonia, apathy, and anergia in older adults with and without cognitive impairment or dementia.
Int J Geriatr Psychiatry. 2008;23(10):1040-1050.
PubMedGoogle ScholarCrossref 88.Versluis
CE, van der Mast
RC, van Buchem
MA,
et al. PROSPER Study. Progression of cerebral white matter lesions is not associated with development of depressive symptoms in elderly subjects at risk of cardiovascular disease: The PROSPER Study.
Int J Geriatr Psychiatry. 2006;21(4):375-381.
PubMedGoogle ScholarCrossref 89.Steffens
DC, Krishnan
KR, Crump
C, Burke
GL. Cerebrovascular disease and evolution of depressive symptoms in the cardiovascular health study.
Stroke. 2002;33(6):1636-1644.
PubMedGoogle ScholarCrossref 90.Teodorczuk
A, Firbank
MJ, Pantoni
L,
et al. LADIS Group. Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study.
Psychol Med. 2010;40(4):603-610.
PubMedGoogle ScholarCrossref 91.Direk
N, Perez
HS, Akoudad
S,
et al. Markers of cerebral small vessel disease and severity of depression in the general population.
Psychiatry Res. 2016;253:1-6.
PubMedGoogle ScholarCrossref 93.Pantoni
L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges.
Lancet Neurol. 2010;9(7):689-701.
PubMedGoogle ScholarCrossref 94.Herrmann
LL, Le Masurier
M, Ebmeier
KP. White matter hyperintensities in late life depression: a systematic review.
J Neurol Neurosurg Psychiatry. 2008;79(6):619-624.
PubMedGoogle ScholarCrossref 95.Taylor
WD, Aizenstein
HJ, Alexopoulos
GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression.
Mol Psychiatry. 2013;18(9):963-974.
PubMedGoogle ScholarCrossref 98.Santos
M, Xekardaki
A, Kövari
E, Gold
G, Bouras
C, Giannakopoulos
P. Microvascular pathology in late-life depression.
J Neurol Sci. 2012;322(1-2):46-49.
PubMedGoogle ScholarCrossref 99.van Dijk
EJ, Prins
ND, Vermeer
SE,
et al. C-reactive protein and cerebral small-vessel disease: The Rotterdam Scan Study.
Circulation. 2005;112(6):900-905.
PubMedGoogle ScholarCrossref 100.Dantzer
R, O’Connor
JC, Freund
GG, Johnson
RW, Kelley
KW. From inflammation to sickness and depression: when the immune system subjugates the brain.
Nat Rev Neurosci. 2008;9(1):46-56.
PubMedGoogle ScholarCrossref 102.Stehouwer
CD, Gall
MA, Twisk
JW, Knudsen
E, Emeis
JJ, Parving
HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death.
Diabetes. 2002;51(4):1157-1165.
PubMedGoogle ScholarCrossref 103.Ng
F, Berk
M, Dean
O, Bush
AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications.
Int J Neuropsychopharmacol. 2008;11(6):851-876.
PubMedGoogle ScholarCrossref 104.Valko
M, Leibfritz
D, Moncol
J, Cronin
MT, Mazur
M, Telser
J. Free radicals and antioxidants in normal physiological functions and human disease.
Int J Biochem Cell Biol. 2007;39(1):44-84.
PubMedGoogle ScholarCrossref 108.van Sloten
TT, Mitchell
GF, Sigurdsson
S,
et al. Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease: cross-sectional findings from the AGES-Reykjavik Study.
J Psychiatry Neurosci. 2016;41(3):162-168.
PubMedGoogle ScholarCrossref 109.Mitchell
GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage.
J Appl Physiol (1985). 2008;105(5):1652-1660.
PubMedGoogle ScholarCrossref 110.O’Rourke
MF, Safar
ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy.
Hypertension. 2005;46(1):200-204.
PubMedGoogle ScholarCrossref 111.Machado
MV, Vieira
AB, Nascimento
AR,
et al. Physical exercise restores microvascular function in obese rats with metabolic syndrome.
Metab Syndr Relat Disord. 2014;12(9):484-492.
PubMedGoogle ScholarCrossref 112.Rossi
M, Pistelli
F, Pesce
M,
et al. Impact of long-term exposure to cigarette smoking on skin microvascular function.
Microvasc Res. 2014;93:46-51.
PubMedGoogle ScholarCrossref 113.Muris
DM, Houben
AJ, Kroon
AA,
et al. Age, waist circumference, and blood pressure are associated with skin microvascular flow motion: the Maastricht Study.
J Hypertens. 2014;32(12):2439-2449.
PubMedGoogle ScholarCrossref 114.Karaca
Ü, Schram
MT, Houben
AJ, Muris
DM, Stehouwer
CD. Microvascular dysfunction as a link between obesity, insulin resistance and hypertension.
Diabetes Res Clin Pract. 2014;103(3):382-387.
PubMedGoogle ScholarCrossref 115.Muris
DM, Houben
AJ, Schram
MT, Stehouwer
CD. Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis.
Arterioscler Thromb Vasc Biol. 2012;32(12):3082-3094.
PubMedGoogle ScholarCrossref 116.Verger
P, Lions
C, Ventelou
B. Is depression associated with health risk-related behaviour clusters in adults?
Eur J Public Health. 2009;19(6):618-624.
PubMedGoogle ScholarCrossref 117.Aoqui
C, Chmielewski
S, Scherer
E,
et al. Microvascular dysfunction in the course of metabolic syndrome induced by high-fat diet.
Cardiovasc Diabetol. 2014;13:31.
PubMedGoogle ScholarCrossref 118.Penninx
BW. Depression and cardiovascular disease: Epidemiological evidence on their linking mechanisms.
Neurosci Biobehav Rev. 2017;74(pt B):277-286.
PubMedGoogle ScholarCrossref 120.Moody
DM, Brown
WR, Challa
VR, Ghazi-Birry
HS, Reboussin
DM. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer’s disease.
Ann N Y Acad Sci. 1997;826:103-116.
PubMedGoogle ScholarCrossref 121.González
HM, Tarraf
W, Whitfield
K, Gallo
JJ. Vascular depression prevalence and epidemiology in the United States.
J Psychiatr Res. 2012;46(4):456-461.
PubMedGoogle ScholarCrossref 122.Wardlaw
JM, Smith
C, Dichgans
M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging.
Lancet Neurol. 2013;12(5):483-497.
PubMedGoogle ScholarCrossref 123.Østergaard
L, Engedal
TS, Moreton
F,
et al. Cerebral small vessel disease: capillary pathways to stroke and cognitive decline.
J Cereb Blood Flow Metab. 2016;36(2):302-325.
PubMedGoogle ScholarCrossref 124.Benjamin
P, Viessmann
O, MacKinnon
AD, Jezzard
P, Markus
HS. 7 Tesla MRI in cerebral small vessel disease.
Int J Stroke. 2015;10(5):659-664.
PubMedGoogle ScholarCrossref 125.Brookes
RL, Herbert
V, Lawrence
AJ, Morris
RG, Markus
HS. Depression in small-vessel disease relates to white matter ultrastructural damage, not disability.
Neurology. 2014;83(16):1417-1423.
PubMedGoogle ScholarCrossref 126.Lamar
M, Charlton
RA, Morris
RG, Markus
HS. The impact of subcortical white matter disease on mood in euthymic older adults: a diffusion tensor imaging study.
Am J Geriatr Psychiatry. 2010;18(7):634-642.
PubMedGoogle ScholarCrossref 127.van Uden
IW, Tuladhar
AM, de Laat
KF,
et al. White matter integrity and depressive symptoms in cerebral small vessel disease: the RUN DMC study.
Am J Geriatr Psychiatry. 2015;23(5):525-535.
PubMedGoogle ScholarCrossref 128.Martens
RJ, Vink
H, van Oostenbrugge
RJ, Staals
J. Sublingual microvascular glycocalyx dimensions in lacunar stroke patients.
Cerebrovasc Dis. 2013;35(5):451-454.
PubMedGoogle ScholarCrossref 129.Sörensen
BM, Houben
AJ, Berendschot
TT,
et al. Prediabetes and type 2 diabetes are associated with generalized microvascular dysfunction: the Maastricht Study.
Circulation. 2016;134(18):1339-1352.
PubMedGoogle ScholarCrossref 130.Gronenschild
EH, Muris
DM, Schram
MT, Karaca
U, Stehouwer
CD, Houben
AJ. Semi-automatic assessment of skin capillary density: proof of principle and validation.
Microvasc Res. 2013;90:192-198.
PubMedGoogle ScholarCrossref 131.Mangiacapra
F, Peace
AJ, Di Serafino
L,
et al. Intracoronary EnalaPrilat to Reduce MICROvascular Damage During Percutaneous Coronary Intervention (ProMicro) Study.
J Am Coll Cardiol. 2013;61(6):615-621.
PubMedGoogle ScholarCrossref 132.Fujii
K, Kawasaki
D, Oka
K,
et al. The impact of pravastatin pre-treatment on periprocedural microcirculatory damage in patients undergoing percutaneous coronary intervention.
JACC Cardiovasc Interv. 2011;4(5):513-520.
PubMedGoogle ScholarCrossref 133.Holowatz
LA, Santhanam
L, Webb
A, Berkowitz
DE, Kenney
WL. Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans.
J Physiol. 2011;589(pt 8):2093-2103.
PubMedGoogle ScholarCrossref 134.Lanting
SM, Johnson
NA, Baker
MK, Caterson
ID, Chuter
VH. The effect of exercise training on cutaneous microvascular reactivity: a systematic review and meta-analysis.
J Sci Med Sport. 2017;20(2):170-177.
PubMedGoogle ScholarCrossref 135.Leardini-Tristao
M, Borges
JP, Freitas
F,
et al. The impact of early aerobic exercise on brain microvascular alterations induced by cerebral hypoperfusion.
Brain Res. 2017;1657:43-51.
PubMedGoogle ScholarCrossref 136.Espeland
MA, Erickson
K, Neiberg
RH,
et al. Action for Health in Diabetes Brain Magnetic Resonance Imaging (Look AHEAD Brain) Ancillary Study Research Group. Brain and white matter hyperintensity volumes after 10 years of random assignment to lifestyle intervention.
Diabetes Care. 2016;39(5):764-771.
PubMedGoogle ScholarCrossref 137.Vuckovic
A, Cohen
BM, Zubenko
GS. The use of captopril in treatment-resistant depression: an open trial.
J Clin Psychopharmacol. 1991;11(6):395-396.
PubMedGoogle ScholarCrossref 138.Celano
CM, Freudenreich
O, Fernandez-Robles
C, Stern
TA, Caro
MA, Huffman
JC. Depressogenic effects of medications: a review.
Dialogues Clin Neurosci. 2011;13(1):109-125.
PubMedGoogle Scholar 139.Germain
L, Chouinard
G. Captopril treatment of major depression with serial measurements of blood cortisol concentrations.
Biol Psychiatry. 1989;25(4):489-493.
PubMedGoogle ScholarCrossref 141.Santanello
NC, Barber
BL, Applegate
WB,
et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study.
J Am Geriatr Soc. 1997;45(1):8-14.
PubMedGoogle ScholarCrossref 142.Muldoon
MF, Barger
SD, Ryan
CM,
et al. Effects of lovastatin on cognitive function and psychological well-being.
Am J Med. 2000;108(7):538-546.
PubMedGoogle ScholarCrossref 143.Stewart
RA, Sharples
KJ, North
FM, Menkes
DB, Baker
J, Simes
J; The LIPID Study Investigators. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin.
Arch Intern Med. 2000;160(20):3144-3152.
PubMedGoogle ScholarCrossref 144.Yang
CC, Jick
SS, Jick
H. Lipid-lowering drugs and the risk of depression and suicidal behavior.
Arch Intern Med. 2003;163(16):1926-1932.
PubMedGoogle ScholarCrossref 145.Young-Xu
Y, Chan
KA, Liao
JK, Ravid
S, Blatt
CM. Long-term statin use and psychological well-being.
J Am Coll Cardiol. 2003;42(4):690-697.
PubMedGoogle ScholarCrossref